Merck & Company Inc (MRK) carries a ŷRobot AI score of 61 out of 100. The model's fair value estimate is $154.73, 8.6% above the last close of $142.41. The chart signal reads Hold.
| Metric | MRK |
|---|---|
| AI score | 61 / 100 |
| Chart signal | Hold |
| Fair value estimate | $154.73 |
| Upside to fair value | 8.6% |
| Previous close | $142.41 |
| P/E | 115.98 |
| Price / sales | 5.35 |
| Market cap | $350.19B |
| EPS | 1.24 |
| Revenue growth | 3.4% |
| 1-year price change | 6.1% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Novartis AG ADR, Thermo Fisher Scientific Inc.
As of Oct 8, 2026, ŷRobot's fair-value model estimates Merck & Company Inc (MRK) at $154.73 against a last close of $142.41, implying 8.6% upside to the model's estimate.
The chart-signal model classifies MRK as Neutral as of Oct 8, 2026, with a signal score of 0.03 on a -1 to 1 scale.
MRK scores 61 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 8, 2026.
MRK trades at 116.0 times earnings and 5.3 times sales as of Oct 8, 2026.
ŷRobot's seasonal forecast curve for MRK reads -2.0% at 30 days, +2.8% at 90 days, and +6.1% at one year as of Oct 8, 2026. Seasonal tendencies are historical patterns, not predictions.
Merck & Company Inc's revenue growth is +3.4% and free-cash-flow growth is -142.7% on the latest reported figures.
MRK chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.